A US retrospective cohort study found no association between angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) use and COVID-19 test positivity. The study included 18 472 patients tested for COVID-19 (mean age 49 years, 40% male, and 69% white), 12.4% were taking either ACEIs or ARBs. A positive COVID-19 test result was observed in 9.4% of patients. Among patients who tested positive, 24.3% were admitted to the hospital, 9.3% were admitted to an intensive care unit, and 6.4% required mechanical ventilation. Overlap propensity score weighting showed no significant association of ACEI and/or ARB use with COVID-19 test positivity. These data support various society guidelines to continue current treatment of chronic disease conditions with either ACEI or ARB during the COVID-19 pandemic. Source: https://jamanetwork.com/
A study revealed that stroke remains a major global health challenge, influenced by numerous risk…
A systematic review and meta-analysis evaluated randomized controlled trials on pharmacological treatments for anxiety in…
A global study suggested that most patients with coronary heart disease (CHD) have Lipoprotein (a)…
A recent article explored the science and skepticism surrounding seed oils. These oils—extracted from sources…
A Canadian study of adults with high blood pressure (BP) found no difference in health…
Two randomized, controlled trials evaluated the efficacy and safety of obicetrapib, an oral cholesteryl ester…
This website uses cookies.